Skip to main content
Top of the Page

Sagar Lonial, MD, FACP, on Why This MRD Approach Is 'Premature' in MM


Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.

Listen to the podcast HERE.

Catch up on earlier episodes of The HemOnc Pulse here.




Back to Top